FindTrial
Sign In

Blood test to detect venomous snake bite

Assessing for Utility of Phospholipase A2 ELISA in Snakebite victims - Nil

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/07/089960
Enrollment
200
Registered
2025-07-02
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: X398- Other exposure to forces of nature

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil Intervention4: Nil: Nil Intervention5: Nil: Nil

Sponsors

FMCI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients coming with history of snake bite

Exclusion criteria

Exclusion criteria: History of chronic inflammatory diseases or autoimmune conditions, use of anti-venom before hospital admission, patients on medications that may influence PLA2 levels (e.g., steroids, NSAIDs and amiodarone) Patients who have received Anti snake venom from outside hospital.

Design outcomes

Primary

MeasureTime frame
Utility of PLA2 in snake bite patientsTimepoint: On arrival - 0 hour and 3 hours after anti snake venom—

Secondary

MeasureTime frame
Correlation of snakebite severity score & morbidityTimepoint: On admission - 0 hours & at time of discharge—

Countries

India

Contacts

Public ContactDr Shailaja S

Father Muller Medical College

drshaila@fathermuller.in9845663466

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026